Rock Springs Capital Management’s Cytokinetics CYTK Stock Holding History

Rock Springs Capital Management’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$16M	Buy	187,980 +142,616	+314%	+$10.2M	0.78%	41
2026 Q1	$2.99M	Buy	45,364 +9,511	+27%	+$604K	0.18%	78
2025 Q4	$2.28M	Buy	+35,853	New	+$2.23M	0.12%	87
2024 Q4	–	Sell	-206,108	Closed	-$10.9M	–	111
2024 Q3	$10.9M	Buy	+206,108	New	+$11.5M	0.35%	65
2023 Q4	–	Sell	-134,252	Closed	-$3.96M	–	107
2023 Q3	$3.96M	Sell	134,252 -313,348	-70%	-$10.4M	0.11%	87
2023 Q2	$14.6M	Hold	447,600	–	–	0.35%	66
2023 Q1	$15.8M	Buy	447,600 +4,600	+1%	+$188K	0.38%	65
2022 Q4	$20.3M	Hold	443,000	–	–	0.49%	56
2022 Q3	$21.5M	Buy	443,000 +43,000	+11%	+$2.07M	0.55%	53
2022 Q2	$15.7M	Buy	+400,000	New	+$16.1M	0.46%	59
2020 Q4	–	Sell	-206,495	Closed	-$4.47M	–	158
2020 Q3	$4.47M	Buy	206,495 +129,078	+167%	+$3.02M	0.11%	133
2020 Q2	$1.82M	Buy	+77,417	New	+$1.45M	0.05%	136

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Rock Springs Capital Management's CYTK Position: Q2 2026 in Review

Rock Springs Capital Management increased its Cytokinetics (CYTK) stake by 314% in Q2 2026, buying an estimated $10.2M and bringing the position to 187,980 shares worth $16M. The position accounts for 0.78% of the portfolio, ranked #41.

Rock Springs Capital Management first reported a position in CYTK in Q2 2020 and has held it in 12 quarters since. The position peaked at $21.5M in Q3 2022. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

Rock Springs Capital Management held 187,980 shares of Cytokinetics worth $16M as of Q2 2026.
Rock Springs Capital Management bought 142,616 Cytokinetics shares in Q2 2026, an estimated $10.2M.
Cytokinetics made up 0.78% of Rock Springs Capital Management's portfolio in Q2 2026, its #41 holding.
Rock Springs Capital Management first reported a position in Cytokinetics in Q2 2020 and has held it in 12 quarters since.
Rock Springs Capital Management's Cytokinetics position peaked at $21.5M in Q3 2022.
482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Rock Springs Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.